In the latest quarter, 14 analysts provided ratings for Sarepta Therapeutics SRPT, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 3 | 5 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 5 | 3 | 4 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $157.21, with a high estimate of $224.00 and a low estimate of $128.00. Observing a 8.14% increase, the current average has risen from the previous average price target of $145.38.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | - |
| Gil Blum | Needham | Maintains | Buy | $166.00 | - |
| Colin Bristow | UBS | Raises | Buy | $167.00 | $164.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | - |
| Brian Abrahams | RBC Capital | Raises | Outperform | $157.00 | $151.00 |
| David Hoang | Citigroup | Raises | Buy | $172.00 | $160.00 |
| Gena Wang | Barclays | Raises | Overweight | $185.00 | $141.00 |
| Gil Blum | Needham | Lowers | Buy | $166.00 | $169.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Raises | In-Line | $138.00 | $108.00 |
| Andreas Argyrides | Wedbush | Maintains | Outperform | $224.00 | - |
| Gil Blum | Needham | Raises | Buy | $169.00 | $140.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | - |
| Uy Ear | Mizuho | Raises | Buy | $145.00 | $130.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Neutral | $128.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sarepta Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Key Indicators: Sarepta Therapeutics's Financial Health
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Sarepta Therapeutics showcased positive performance, achieving a revenue growth rate of 53.54% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.51%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.43%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.63, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
